New CMS rules show MiMedx, Osiris get pass-throughs for EpiFix, Grafix

Shares of MiMedx Group (MDXG +6.1%) are stronger in early trading after the CMS issued final payment rules for HOPPS.

EpiFix gets a pass-through for 2014 — it retains the current payment methodology (ASP +6%) for one more year.

Here's CEO Parker Petit commenting on the new two-tier payment system adopted by CMS: "We believe this new ... reimbursement policy will reduce excessive spending and broaden patient access to advanced wound care, which will benefit Medicare recipients. We applaud CMS for making this policy change." (PR)

Also, Osiris Therapeutics (OSIR +4.5%) looks to have gotten a two-year pass-through for Grafix.

Meanwhile, SA contributor Jason Napodano doesn't sound optimistic on either MDXG or OSIR. See here and here.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs